Complexed PSA performance for prostate cancer detection in an African-American population

Urology

Volumn 62, Issue 5, 2003, Pages 835-839

  Martin, B ^b   Cheli, C D ^b   Lifsey, D ^b   Ward, M ^b   Pollard, S ^b   Jefferson, L ^b   Thiel, R P ^b   Rayford, W ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RACE; SERUM; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 0242495794     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00675-7     Document Type: Article

References (29)

1. Stephan C., Jung K., Lein M., et al. Molecular forms of prostatic-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;1133-1147.
2. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
3. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage free prostatic specific antigen to enhance differentiation of prostate cancer from benign prostate disease a prospective multicenter trial. JAMA. 279:1998;1542-1547.
4. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination enhancement of specificity with free PSA measurements. JAMA. 277:1997;1452-1455.
5. Allard W.J., Zhou Z., Yeung K.K. Novel immunoassay for the measurement of complexed prostate specific antigen in serum. Clin Chem. 44:1998;1216-1223.
6. Sokoll L.J., Bruzek D.J., Dua R. Short term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology. 60:(suppl 4A):2002;24-30.
7. Allard W.J., Chelli C.D., Morris D.L., et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno-1 complexed PSA assay. Int J Biol Markers. 14:1999;73-83.
8. Brawer M.K., Meyer G.E., Letran J.L. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
9. Brawer M.K., Cheli C.D., Neaman I.E. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 163:2000;1476-1480.
10. Maeda H., Arai Y., Aoki Y., et al. Complexed prostate-specific antigen and its volume indices in the detection of prostate cancer. Urology. 54:1999;225-228.
11. Djavan B., Remzi M., Zlotta A.R. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate specific antigen ratio, density of total and transition zone prostate-specific antigen results of the prospective multicenter European trial. Urology. 60:(suppl 4A):2002;4-9.
12. Taneja S.S., Hsu E.I., Cheli C.D. Complexed prostate-specific antigen as a staging tool results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology. 60:(suppl 4A):2002;10-17.
13. Okihara K., Cheli C.D., Partin A.W., et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 167:2002;2017-2024.
14. Tanguay S., Begin L.R., Elihilali M.M., et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology. 59:2002;261-265.
15. Okihara K., Fritsche H.A., Ayala A., et al. Can complexed prostate specific antigen and prostate volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/mL? J Urol. 165:2001;1930-1936.
16. Horninger W., Cheli C.D., Babaian R.J. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate specific-antigen levels of 2 to 4 nanograms per milliliter. Urology. 60:(suppl 4A):2002;31-35.
17. Smith D.S., Carvalhal G.F., Mager D.E., et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 160:1998;1734-1738.
18. Ries LAG, Eisner MP, Kosay CL, et al. SEER Cancer Statistics Review, 1973-1998. Bethesda, National Cancer Institute. Available from http://seer.cancer.gov/Publications/CSR1973_1998.
19. Gargiullo P., Wingo P.A., Coates R.J., et al. Recent trends in mortality rates for four major cancers, by sex and race - United States, 1990-1998. Mort Morb Week Rep. 51:2002;49-53.
20. Brawley O.W. Prostate cancer and black men. Semin Urol Oncol. 16:1998;184-186.
21. Montie J.E., Pienta K.J. A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men. Urology. 53:1999;1073-1076.
22. Stamey T.A., Yang N., Hay A.R., et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
23. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 35:1998;275-368.
24. Jani A.B., Vaida F., Hanks G., et al. Changing face and different countenances of prostate cancer racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 96:2001;363-371.
25. Paquette E.L., Connelly R.R., Sesterhann I.A., et al. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era. Cancer. 92:2001;2673-2679.
26. Pettaway C.A., Troncoso P., Ramirez E.I., et al. Prostate specific antigen and pathological features of prostate cancer in black and white patients a comparative study based on radical prostatectomy specimens. J Urol. 160:1998;437-442.
27. Eastham J.A., Carver B., Katz J., et al. Clinical stage T1c prostate cancer pathologic outcomes following radical prostatectomy in black and white men. Prostate. 50:2002;236-240.
28. Taylor J.A., Gomcarczyk K.J., Fant G.V., et al. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology. 60:2002;841-845.
29. Fleshner N.E., O'Sullivan M., Fair W.R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol. 158:1997;505-509.